Sensus Healthcare to Present at the H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

Sensus Healthcare (SRTS) announces participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. CEO Joe Sardano will present a pre-recorded session available on-demand starting January 10 at 7:00 a.m. ET. Attendees can access the presentation via the company’s investor relations page. Additionally, Sensus management is open to virtual 1x1 meetings during the J.P. Morgan Healthcare Conference from January 10-14. Interested parties can schedule meetings through email.

Company Management Available for 1x1 Meetings Concurrent with the 40th Annual J.P. Morgan Healthcare Conference January 10-14

BOCA RATON, Fla. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Joe Sardano, chairman and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022.  A pre-recorded presentation will be available on demand beginning Monday, January 10 at 7:00 a.m. Eastern time. Interested parties can access the presentation on the investor relations section of the Company’s website and at this link.

Also, Sensus management is holding virtual 1x1 meetings with members of the investment community concurrent with the 40^th Annual J.P. Morgan Healthcare Conference January 10-14, 2022.  Please email kgolodetz@lhai.com to schedule a meeting.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted directional anisotropic radiation therapy (ART) and brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit www.sensushealthcare.com.

Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

#   #   #

FAQ

What is the date of the H.C. Wainwright BioConnect Virtual Conference for Sensus Healthcare (SRTS)?

The H.C. Wainwright BioConnect Virtual Conference for Sensus Healthcare will take place from January 10-13, 2022.

Where can I access the presentation from Sensus Healthcare (SRTS) at the H.C. Wainwright Conference?

The presentation from Sensus Healthcare can be accessed on the investor relations section of the company’s website starting January 10, 2022.

How can I schedule a 1x1 meeting with Sensus Healthcare (SRTS) management?

To schedule a 1x1 meeting with Sensus Healthcare management, you can email kgolodetz@lhai.com.

Who is presenting for Sensus Healthcare (SRTS) at the upcoming conference?

Joe Sardano, the chairman and CEO of Sensus Healthcare, will be presenting at the conference.

What innovative technologies does Sensus Healthcare (SRTS) specialize in?

Sensus Healthcare specializes in non-invasive and minimally-invasive treatments for oncological and non-oncological conditions, including technologies like Sculptura™ and SRT systems.